top of page
Rexulti (brexpiprazole) is classified as an atypical antipsychotic used as an adjunctive therapy to antidepressants to treatmajor depressive disorder (MDD)in adults and for the treatment ofschizophreniain adults and pediatric patients who are at least 13 years old. Rexulti is available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg tablets. Fact Table Formula C25H27N3O2S License US DailyMed, EU EMA, US FDA Bioavailability 95% Legal status Rx-Only Chemical Name Brexpiprazole Elimination half-life 91 hours Dosage (Strength) 0.25mg - 4mg Pregnancy Consult Doctor Brands Rexulti Protein binding Greater than 99% PubChem CID 11978813 MedlinePlus a615046 ChEBI 134716 ATC code N05AX16 DrugBank DB09128 KEGG D10309 Routes of administration By mouth

Rexulti (Brexpiprazole)

  • Rexulti is taken by mouth once daily with or without food. MDD in adults Starting dose: 0.5 mg/day or 1 mg/day Recommended dose: 2 mg/day Max dose: 3 mg/day Schizophrenia in adults Starting dose: 1 mg/day Recommended dose: 2 to 4 mg/day Max dose: 4 mg/day Schizophrenia in pediatric patients (13-17 years old) Starting dose: 0.5 mg/day Recommended dose: 2 to 4 mg/day Max dose: 4 mg/day
bottom of page